Sarepta Therapeutics, Inc.

SRPTleader

Sarepta Therapeutics is the leader in treatments for Duchenne muscular dystrophy (DMD) — a fatal muscle-wasting disease affecting young boys. Its gene therapy Elevidys is the first approved treatment to address the genetic root cause.

⇄ Compare

Products & Revenue

Product Revenue Share

Revenue Breakdown ($1.9B)

Static data (loading live financials…)

Elevidys (40%)

Exondys 51 + Other Exon Skipping (60%)

Segment Breakdown & Key Customers

Product Details

Elevidys (Delandistrogene Moxeparvovec)55%

First FDA-approved gene therapy for Duchenne muscular dystrophy — one-time treatment targeting the root cause.

Exon Skipping Drugs (Exondys/Vyondys/Amondys)45%

Exon 51/53/45 skipping drugs — monthly IV infusions for specific DMD mutations.

Supply Chain Relationships

Partners

roche

Elevidys co-promotion (Roche/Genentech in ex-US)

Impact: significant

Macro & Market Context

헬스케어Sector News

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Upcoming Catalysts

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Latest News

Loading news...

AI Analysis

Click "Get AI Analysis" for an AI-powered supply chain analysis of Sarepta Therapeutics, Inc..

Company Info

Headquarters

Cambridge, MA

Founded

1980

Employees

1,900

Website

sarepta.com

Sector Overview — 헬스케어

Sector News